Short Interest in Oculis Holding AG (NASDAQ:OCSAW) Decreases By 43.2%

Oculis Holding AG (NASDAQ:OCSAW) was the recipient of a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 4,485 shares, a decline of 43.2% from the June 15th total of 7,902 shares. Based on an average daily trading volume, of 4,538 shares, the short-interest ratio is currently 1.0 days.

Oculis Stock Performance

OCSAW stock traded down $0.20 during trading on Thursday, reaching $4.57. The stock had a trading volume of 17,274 shares, compared to its average volume of 6,032. The firm has a fifty day moving average price of $9.61 and a 200 day moving average price of $13.12. Oculis has a 1-year low of $3.63 and a 1-year high of $22.64.

Oculis Company Profile

Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.

Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.